<!DOCTYPE html>
<html lang="en-gb" dir="ltr">

  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title>Novogen</title>
    <link rel="apple-touch-icon" sizes="57x57" href="img/favicons/apple-touch-icon-114x114.png">
    <link rel="apple-touch-icon" sizes="114x114" href="img/favicons/apple-touch-icon-114x114.png">
    <link rel="apple-touch-icon" sizes="72x72" href="img/favicons/apple-touch-icon-72x72.png">
    <link rel="apple-touch-icon" sizes="144x144" href="img/favicons/apple-touch-icon-144x144.png">
    <link rel="apple-touch-icon" sizes="60x60" href="img/favicons/apple-touch-icon-60x60.png">
    <link rel="apple-touch-icon" sizes="120x120" href="img/favicons/apple-touch-icon-120x120.png">
    <link rel="apple-touch-icon" sizes="76x76" href="img/favicons/apple-touch-icon-76x76.png">
    <link rel="apple-touch-icon" sizes="152x152" href="img/favicons/apple-touch-icon-152x152.png">
    <link rel="apple-touch-icon" sizes="180x180" href="img/favicons/apple-touch-icon-180x180.png">
    <link rel="icon" type="image/png" href="img/favicons/favicon-192x192.png" sizes="192x192">
    <link rel="icon" type="image/png" href="img/favicons/favicon-160x160.png" sizes="160x160">
    <link rel="icon" type="image/png" href="img/favicons/favicon-96x96.png" sizes="96x96">
    <link rel="icon" type="image/png" href="img/favicons/favicon-16x16.png" sizes="16x16">
    <link rel="icon" type="image/png" href="img/favicons/favicon-32x32.png" sizes="32x32">
    <meta name="msapplication-TileColor" content="#21c4c2">
    <meta name="msapplication-TileImage" content="img/favicons/mstile-144x144.png">
    <meta name="description" content="Bio-pharmaceutical company using breakthrough technology to create the CS-6
family of drugs to selectively kill cancer stem cells, without side effects.">
    <link href="//maxcdn.bootstrapcdn.com/font-awesome/4.2.0/css/font-awesome.min.css" rel="stylesheet">
    <link href='http://fonts.googleapis.com/css?family=Raleway:400,300,500' rel='stylesheet' type='text/css'>
    <link rel="stylesheet" href="bower_components/uikit/css/mystyle.css">
    <script src="bower_components/jquery/dist/jquery.min.js"></script>
    <script src="bower_components/uikit/js/uikit.min.js"></script>
    <script src="bower_components/uikit/js/core/offcanvas.min.js"></script>
    <script src="bower_components/uikit/js/components/slideshow.min.js"></script>
    <script src="bower_components/uikit/js/components/slideshow-fx.min.js"></script>
    <script src="bower_components/uikit/js/components/cover.min.js"></script>
    <script src="bower_components/uikit/js/components/sticky.min.js"></script>
  </head>

  <body>
    <div class="social-bar uk-vertical-align">
      <div class="share-icons uk-vertical-align-middle uk-grid uk-width-1-1">
        <span class="share-wrap uk-width-1-2">
          <a href="http://www.nasdaq.com/symbol/nvgn" target="_blank"><img src="img/nasdaq.svg" class="nasdaq-top">
            <a href="http://www.asx.com.au/asx/research/companyInfo.do?by=asxCode&asxCode=NRT" target="_blank"><img src="img/ASX.svg" class="asx-top "></a>
            </span>
          <span class="social-wrap uk-width-1-2">
            <a href="https://twitter.com/Novogen" target="_blank"><img src="img/twitter.png" class="twitter-top uk-float-right"></a>
            <a href="https://www.linkedin.com/company/novogen" target="_blank"><img src="img/LinkedIn.svg" class="linkedin-top uk-float-right"></a>
            <a href="https://www.youtube.com/channel/UCzNMflCMfqL-kTzanKU-gDQ" target="_blank"><img src="img/youtube.svg" class="utube-top uk-float-right"></a>
          </span>
          </div>

      </div>
      <nav class="uk-navbar uk-navbar-attached" data-uk-sticky>
        <a class="logo uk-navbar-brand" href="index.html"><img src="img/novogen-logo.svg" alt="Novogen Logo with white writing on dark background"></a>
        <ul class="uk-navbar-nav uk-navbar-flip uk-hidden-small">
          <li class="menu-item" data-uk-dropdown><a href="#">About</a>
            <div class="long-list uk-dropdown uk-dropdown-navbar">
              <ul class="uk-nav uk-nav-navbar">
                <li><a href="history.html">History</a></li>
                <li><a href="news.html">News</a></li>
                <!--                <li><a href="#">CEO</a></li>-->
                <li><a href="theboard.html">The Board</a></li>
                <li><a href="management.html">Management Team</a></li>
                <li><a href="blog.html">CEO Corner</a></li>
              </ul>
            </div>
          </li>
          <li class="menu-item" data-uk-dropdown><a href="programs.html">Pipeline</a>

            <div class="longer-list uk-dropdown uk-dropdown-navbar">
              <ul class="uk-nav uk-nav-navbar">
                <li><a href="#sbp-box" data-uk-modal>SUPER-BENZOPYRAN DRUG TECHNOLOGY</a></li>
                <li><a href="#anti-box" data-uk-modal>ANTI-TROPOMYOSINS DRUG TECHNOLOGY</a></li>
                <li><a href="#cantx-box" data-uk-modal>CANTX PROGRAM</a></li>
                <li><a href="#jacob-box" data-uk-modal>PROJECT JACOB HOPE</a></li>
              </ul>
            </div>

          </li>
          <li class="menu-item" data-uk-dropdown><a href="investors.html">Investors</a>
            <div class="long-list uk-dropdown uk-dropdown-navbar">
              <ul class="uk-nav uk-nav-navbar">
                <li><a href="latest-presentations.html">LATEST PRESENTATIONS</a></li>
                <li><a href="media.html">MEDIA</a></li>
                <li><a href="news.html">NEWS</a></li>
                <li><a href="meip.html">MEIP IN-SPECIE DISTRIBUTION</a></li>
                <li><a href="corporate-governance.html">CORPORATE GOVERNANCE</a></li>
                <li><a href="shares.html">SHARE PRICE</a></li>
                <li><a href="sec.html">SEC FILINGS</a></li>
                <li><a href="asx.html">ASX ANNOUNCEMENTS</a></li>
                <li><a href="analyst-reports.html">ANALYST REPORTS</a></li>
                <li><a href="annual-reports.html">ANNUAL REPORTS</a></li>
              </ul>
            </div>
          </li>
          <li class="menu-item"><a href="contact.html">Contact</a></li>
        </ul>
        <a href="#mobi-nav" class="uk-navbar-toggle uk-visible-small uk-float-right" data-uk-offcanvas>MENU </a>
      </nav>
      <div id="mobi-nav" class="uk-offcanvas">

        <div class="uk-offcanvas-bar">

          <ul class="uk-nav uk-nav-offcanvas uk-nav-parent-icon" data-uk-nav>
            <li><a href="">MENU</a></li>
            <li class="uk-active"><a href="index.html">HOME</a></li>

            <li class="uk-parent">
              <a href="#">ABOUT</a>
              <ul class="uk-nav uk-subnav">
               <li><a href="about.html">ABOUT PAGE</a></li><br>
                <li><a href="history.html">HISTORY</a></li><br>
                <!--                <li><a href="#">VISION</a></li>-->
                <!--                <li><a href="#">CEO</a></li>-->
                <li><a href="theboard.html">THE BOARD</a></li><br>
                <li><a href="management.html">MANAGEMENT TEAM</a></li><br>
              </ul>
            </li>

            <li class="uk-parent">
              <a href="programs.html">PIPELINE</a>
              <ul class="uk-nav uk-subnav">
               <li><a href="programs.html">PIPELINE PAGE</a></li><br>
                <li><a href="#sbp-box" data-uk-modal>SUPER-BENZOPYRAN DRUG TECHNOLOGY</a></li><br>
                <li><a href="#anti-box" data-uk-modal>ANTI-TROPOMYOSINS DRUG TECHNOLOGY</a></li><br>
                <li><a href="#cantx-box" data-uk-modal>CANTX PROGRAM</a></li><br>
                <li><a href="#jacob-box" data-uk-modal>PROJECT JACOB HOPE</a></li><br>
              </ul>
            </li>
            <li class="uk-parent">
              <a href="#">INVESTORS</a>
              <ul class="uk-nav uk-subnav">
<!--               <li><a href="">INVESTORS PAGE</a></li><br>-->
                <li><a href="latest-presentations.html">LATEST PRESENTATIONS</a></li><br>
                <li><a href="media.html">MEDIA</a></li><br>
                <li><a href="news.html">NEWSLETTERS</a></li><br>
                <li><a href="meip.html">MEIP IN-SPECIE DISTRIBUTION</a></li><br>
                <li><a href="corporate-governance.html">CORPORATE GOVERNANCE</a></li><br>
                <li><a href="shares.html">SHARE PRICE</a></li><br>
                <li><a href="sec.html">SEC FILINGS</a></li><br>
                <li><a href="asx.html">ASX FILINGS</a></li><br>
                <li><a href="analyst-reports.html">ANALYST REPORTS</a></li>
                <li><a href="annual-reports.html">ANNUAL REPORTS</a></li>
                <ul>
                  <li><a href="http://www.asx.com.au/asx/research/companyInfo.do?by=asxCode&asxCode=NRT" target="_blank">ASX</a></li>
                  <li><a href="http://www.nasdaq.com/symbol/nvgn" target="_blank">Nasdaq</a></li>
                </ul>
                </li>
          </ul>
          </li>

        <li class="uk-nav-header">Connect with us</li>
        <li><a href="contact.html"><i class="uk-icon-envelope-o"></i> Contact</a></li>
        <li><a href="https://www.youtube.com/channel/UCzNMflCMfqL-kTzanKU-gDQ" target="_blank"><i class="uk-icon-youtube"></i> YouTube</a></li>
        <li><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-twitter"></i> Twitter</a></li>
        <li><a href="https://www.linkedin.com/company/novogen" target="_blank"><i class="uk-icon-linkedin"></i> LinkedIn</a></li>
        <!--
<li class="uk-nav-divider"></li>
<li><a href=""><i class="uk-icon-rss"></i> Item</a></li>
-->
        </ul>

    </div>

    </div>

<div class="about-top uk-vertical-align">
        <div class="uk-vertical-align-middle">
          <h1>The Management Team</h1>
        </div>
      </div>

      <div class="board-member">
        <div class="bm"><img src="img/gkLg.png"></div>
        <div class="bm-topline-wrap">
          <div class="bm-topline"></div>
          <div class="bm-heading">
            <h2 class="uk-margin-bottom-remove">Dr Graham Kelly</h2>
            <h4 class="uk-margin-top-remove">
              B.Sc(Hons),B.VSc(Hons)
              <br>Executive Director &amp; CEO
            </h4>
          </div>
        </div>
        <div class="bm-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

        <div class="bm-bottom-line"></div>
      </div>
      <div class="bm-text">
        <p>
          Dr Kelly is the founder and previous CEO and Chairman of ASX-listed and NASDAQ-listed companies, Novogen Ltd and Marshall Edwards Inc. Both companies were built on the concept of benzopyran drug technology that emanated from his 25 years in cancer research in the Department of Surgery, The University of Sydney, and the German Central Cancer Research Institute, Heidelberg, (Germany) and for which he held all relevant patents.<p>Dr Kelly personally oversaw the design and implementation of thirty-three Phase I and II clinical trials, and a multi-national Phase III trial in conjunction with the US FDA.<br>Dr Kelly has been awarded an Adjunct Professorship by the University of Sydney.
        </p>
      </div>
      <div class="double-lines"></div>

      <div class="boardmember-right">
      <div class="boardmember-box uk-vertical-align uk-text-center uk-hidden-small"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>
<!--      <div class="boardmember-topline"></div>-->
      <div class="boardmember-heading">
            <h2 class="uk-margin-bottom-remove">Dr Andrew Heaton </h2>
            <h4 class="uk-margin-top-remove">
              B.Sc(Hons)Ph.D
              <br>Vice-President, Drug Discovery
            </h4>
          </div>
      <div class="boardmember-image-container"><img class="boardmember-img uk-align-right" src="img/ah.png"
      ></div>

      </div>
            <div class="boardmember-text">
       <p>
          Dr Heaton has extensive drug discovery background. He studied the complex interactions of signalling molecules associated with the mass spawning phenomena on the Great Barrier Reef. Following completion of his Ph.D studies he completed post-doctoral research discovering molecules with unique biological activity from marine environment.
          <p>Dr Heaton first joined Novogen in 1998 as General Manager of the drug discovery program; progressing 4 compounds to clinical trials. He was responsible for the design and execution of the Novogen drug.
        </p>
      </div>
             <div class="double-lines"></div>

        </div>
<!--      </div>-->

      <div class="board-member">
        <div class="bm-coffey"><img src="img/db.png"></div>
        <div class="bm-topline-wrap">
          <div class="bm-topline"></div>
          <div class="bm-heading">
            <h2 class="uk-margin-bottom-remove">Dr David Brown </h2>
            <h4 class="uk-margin-top-remove">
              B.App. Sc. (Hons), PhD, GradDip Technology Mgmt
              <br>Chief Scientific Officer
            </h4>
          </div>
        </div>
        <div class="bm-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

        <div class="bm-bottom-line"></div>
      </div>
      <div class="bm-text">
        <p>
         Dr. David Brown joined Novogen in 2000 and championed the pre-clinical and translational development of Phenoxodiol, Triphendiol, ME-128, ME-143 and ME-344. In 2010, Dr Brown left Novogen and worked as a Medical Advisor for Janssen as part of the Regional Immunology group. Dr Brown is a co-founder of Triaxial Pharmaceuticals and as a result of Novogen’s acquisition of Triaxial re-joined Novogen in 2013 as the company’s Group Chief Scientific Officer where he currently oversees all scientific operations both locally and internationally with our commercial and academic partners. Dr Brown currently sits on the  CanTx Board of Directors, Novogen's joint venture company with Yale University.<p>
          Dr Brown has over 20 years’ experience in all non-clinical aspect of drug discovery and development. He holds a PhD from the University of Queensland, and has held several research appointments at the Queensland Institute of Medical Research (University of Queensland) and University of New South Wales. Dr Brown has co-authored 10 patents, several IND applications, and over 30 peer-reviewed scientific articles
        </p>

      </div>
      <div class="double-lines"></div>


       <div class="boardmember-right">
      <div class="boardmember-box uk-vertical-align uk-text-center uk-hidden-small"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>
<!--      <div class="boardmember-topline"></div>-->
      <div class="boardmember-heading">
            <h2 class="uk-margin-bottom-remove">Dr Justine Stehn </h2>
            <h4 class="uk-margin-top-remove">
              B.Sc(Hons), Ph.D.
              <br>ATM Program Director
            </h4>
          </div>
      <div class="boardmember-image-container"><img class="boardmember-img uk-align-right" src="img/js.png"
      ></div>

      </div>
<!--            <div class="boardmember-bottomline"></div>-->


      <div class="boardmember-text">
        <p>
        Dr Stehn joined Novogen in February 2014 and is responsible for the drug development of the ATM program, which was acquired by Novogen in 2013 and Dr Stehn is also the co-inventor.  Dr Stehn has over 20 years research experience in understanding the role of the cell cytoskeleton in disease. After receiving her PhD from the Garvan Institute of Medical Research, Sydney, Justine was awarded a prestigious National Health and Medical Research Council (NHMRC), CJ Martin Fellowship to support her post doctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT), Boston, USA.
        <p>Upon returning to Australia, Justine headed up the Anti-tropomyosin (ATM) drug development program at UNSW Australia. She has been involved in the ATM program since its inception in 2007 and has been instrumental in driving the preclinical development of the ATM compounds for the treatment of cancer.
        </p>
        <p>
          Previous appointments have included leadership roles as Chair of the Division of Research at The Children’s Hospital at Westmead, Chair of the Westmead Research Hub.  Executive, member of the Board, NSW Cancer Institute and Chair, Board of Bio-Link, a company established by the NSW Government to support commercialisation of biomedical intellectual property.
        </p>
      </div>
      <div class="double-lines"></div>

<div class="board-member">
        <div class="bm-coffey"><img src="img/spalmer.png"></div>
        <div class="bm-topline-wrap">
          <div class="bm-topline"></div>
          <div class="bm-heading">
            <h2 class="uk-margin-bottom-remove">Dr Stephen Palmer </h2>
            <h4 class="uk-margin-top-remove">
              B.Sc(Hons), Ph.D
              <br>Degenerative Diseases Program Director
            </h4>
          </div>
        </div>
        <div class="bm-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

        <div class="bm-bottom-line"></div>
      </div>
      <div class="bm-text">
        <p>
          Dr Palmer joined Novogen in 2014 and is responsible for running the drug discovery programme centred around stimulating regenerative processes in stem cells and developing novel therapies for degenerative diseases including dementia, muscular dystrophy, lysosomal storage disorders and autoimmune disease.</p><p>Dr Palmer completed his PhD in 1992 at University College London and established a career studying the genetic regulation of embryonic development and inherited disorders. Using genetically modified mice as models of human disease, he has studied normal and abnormal cellular function in several different organ systems.
        </p>
<p>
  Dr Palmer migrated to Australia on a Wellcome Trust International Travelling Fellowship and worked at the Victor Chang Cardiac Research Institute and the Children’s Medical Research Institute in Sydney. He established a research program on the neurodevelopmental disorder Williams-Beuren syndrome, demonstrating the key role of the GTF2IRD1 protein. He currently holds a conjoint Senior Lectureship at UNSW Australia.
</p>
      </div>
      <div class="double-lines"></div>

      <div class="boardmember-right">
      <div class="boardmember-box uk-vertical-align uk-text-center uk-hidden-small"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>
<!--      <div class="boardmember-topline"></div>-->
      <div class="boardmember-heading">
            <h2 class="uk-margin-bottom-remove">Lionel Mateo </h2>
            <h4 class="uk-margin-top-remove">
               BCL MCL
              <br>Company Secretary
            </h4>
          </div>
      <div class="boardmember-image-container"><img class="boardmember-img uk-align-right" src="img/lm.png"
      ></div>

      </div>
<!--            <div class="boardmember-bottomline"></div>-->


      <div class="boardmember-text">
        <p>
        Lionel is our resident European on the Novogen team. Growing up in the south of France, Lionel has a Bachelor's degree in Civil Law and a Master's Degree in Civil Law, Economics and Business from the University of Aix en Provence, France.
        <p>Lionel originally had a passion for Criminal Law, but after deciding to settle in Australia, he chose to specialise in corporate governance. Having worked previously for R.M.Williams Agricultural Holdings, first as corporate governance officer, he was then appointed Company Secretary.
        </p>
        <p>
          In late 2013 he joined Novogen as Group Company Secretary and is currently completing the Graduate Diploma in Applied Corporate Governance with the Governance Institute of Australia.
        </p>
      </div>
      <div class="double-lines"></div>

<div class="board-member">
        <div class="bm-coffey"><img src="img/cb.png"></div>
        <div class="bm-topline-wrap">
          <div class="bm-topline"></div>
          <div class="bm-heading">
            <h2 class="uk-margin-bottom-remove">Christine Bruce  </h2>
            <h4 class="uk-margin-top-remove">
              B.Bus (Acc)
              <br>Financial Controller
            </h4>
          </div>
        </div>
        <div class="bm-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

        <div class="bm-bottom-line"></div>
      </div>
      <div class="bm-text">
        <p>
          Christine ASA (CPA Australia) has a Bachelor of Business Degree (Accounting) from the University of Western Sydney.</p><p>Christine joined Novogen in early 2014 after 15 years of successfully running her own defence logistics business as a key supplier to the Australian Department of Defence. She has previously worked for BTR Nylex and Xerox.
        </p>
      </div>
      <div class="double-lines"></div>

          <div id="sbp-box" class="overflow uk-modal">
      <div class="overflow uk-modal-dialog uk-modal-dialog-large uk-height-viewport">
        <a class="uk-modal-close uk-close"></a>
        <iframe src="pdf/Publication_SBPandATM.pdf" class="pdf"></iframe>
      </div>
    </div>
    <div id="anti-box" class="overflow uk-modal">
      <div class="overflow uk-modal-dialog uk-modal-dialog-large uk-height-viewport">
        <a class="uk-modal-close uk-close"></a>
        <iframe src="pdf/atm.pdf" class="pdf"></iframe>
      </div>
    </div>
    <div id="cantx-box" class="overflow uk-modal">
      <div class="overflow uk-modal-dialog uk-modal-dialog-large uk-height-viewport">
        <a class="uk-modal-close uk-close"></a>
        <iframe src="pdf/cantrixil.pdf" class="pdf"></iframe>
      </div>
    </div>
    <div id="jacob-box" class="overflow uk-modal">
      <div class="overflow uk-modal-dialog uk-modal-dialog-large uk-height-viewport">
        <a class="uk-modal-close uk-close"></a>
        <iframe src="pdf/degenerativeDiseases.pdf" class="pdf"></iframe>
      </div>
    </div>

      <footer>
      <div class="uk-grid" style="margin-top: 0">
        <div class="footer-links uk-width-1-2 uk-width-medium-1-4  uk-vertical-align uk-vertical-align-middle">
          <ul class="uk-list">
            <li><a href="#">Home</a></li>
            <li><a href="#">About</a><li>
            <li><a href="#">Pipeline</a></li>
            <li><a href="#">Investors</a></li>
          </ul>
        </div>
        <ul class="shares-footer uk-list uk-list-space uk-hidden-small uk-width-medium-1-4  uk-vertical-align uk-vertical-align-middle">
          <li><a href="http://www.asx.com.au/asx/research/companyInfo.do?by=asxCode&asxCode=NRT" target="_blank"><img src="img/ASX.svg"></a></li>
          <li><a href="http://www.nasdaq.com/symbol/nvgn/sec-filings" target="_blank"><img src="img/nasdaq.svg"></a></li>
        </ul>
        <div class="uk-width-1-2 uk-width-medium-1-4  uk-vertical-align uk-vertical-align-middle">
          <!--
<form class="uk-form">

<fieldset data-uk-margin>
<legend>Sign up to stay informed</legend>
<input type="text" placeholder="you@email.com">
<button class="uk-button">SUBMIT</button>
</fieldset>

</form>
-->

          <form class="uk-form" name="catwebformform83042" method="post" onsubmit="return checkWholeForm83042(this)" enctype="multipart/form-data" action="/FormProcessv2.aspx?WebFormID=84800&OID={module_oid}&OTYPE={module_otype}&EID={module_eid}&CID={module_cid}">
            <fieldset data-uk-margin> <legend> Sign up to stay informed</legend>
              <table class="webform" cellspacing="0" cellpadding="2" border="0"><tr><td><input type="text" placeholder="you@email.com" name="EmailAddress" id="EmailAddress" class="cat_textbox" style="width: 169px" maxlength="255"/> </td></tr><tr><td><input class="cat_button uk-button" type="submit" value="Submit" id="catwebformbutton" /></td></tr></table>
            </fieldset>
            <script type="text/javascript" src="/CatalystScripts/ValidationFunctions.js"></script><script type="text/javascript">
            //<![CDATA[
            var submitcount83042 = 0;function checkWholeForm83042(theForm){var why = "";if (theForm.EmailAddress) why += checkEmail(theForm.EmailAddress.value); if(why != ""){alert(why);return false;}if(submitcount83042 == 0){submitcount83042++;theForm.submit();return false;}else{alert("Form submission is in progress.");return false;}}
            //]]>
            </script></form>



        </div>
        <ul class="social-footer uk-list uk-list-space uk-hidden-small uk-width-medium-1-4 ">
          <li><a href="https://twitter.com/Novogen" target="_blank"><img src="img/twitter.png" class="twitter-bottom uk-align-right"></a></li>
          <li><a href="https://www.linkedin.com/company/novogen" target="_blank"><img src="img/LinkedIn.svg" class="linkedin-bottom uk-align-right"></a></li>
          <li><a href="https://www.youtube.com/channel/UCzNMflCMfqL-kTzanKU-gDQ" target="_blank"><img src="img/youtube.svg" class="utube-bottom uk-align-right"></a></li>
        </ul>

      </div>
    </footer>

  </body>
</html>
